Revenio Group Oyj REG1V.HE · Stock Open Revenio Group Oyj in new tab
Revenio Group Oyj Analysis (REG1V.HE)
Is Revenio Group Oyj a good investment? Revenio Group Oyj (REG1V.HE) is currently trading at 12.56 EUR. Market analysts have a consensus price target of 19.38 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 21.49. This valuation is generally in line with the broader market.
Earnings Schedule: Revenio Group Oyj is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 0.97.
Investor FAQ
Does Revenio Group Oyj pay a dividend?
No, it does not currently pay a dividend.
What asset class is Revenio Group Oyj?
Revenio Group Oyj is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of 0.59.
Company Profile
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
| Year | Total Dividends |
|---|---|
| ▸2025 |
0.40 EUR
|
| April 23, 2025 | 0.4000 |
| ▸2024 |
0.38 EUR
|
| April 15, 2024 | 0.3800 |
| ▸2023 |
0.36 EUR
|
| April 3, 2023 | 0.3600 |
| ▸2022 |
0.34 EUR
|
| April 21, 2022 | 0.3400 |
| ▸2021 |
0.32 EUR
|
| March 26, 2021 | 0.3200 |
| ▸2020 |
0.30 EUR
|
| June 17, 2020 | 0.3000 |
| ▸2019 |
0.56 EUR
|
| March 29, 2019 | 0.5600 |
| ▸2018 |
1.56 EUR
|
| March 29, 2018 | 1.5600 |
| ▸2017 |
1.48 EUR
|
| March 31, 2017 | 1.4800 |
| ▸2016 |
1.40 EUR
|
| March 16, 2016 | 1.4000 |
| ▸2015 |
0.90 EUR
|
| March 20, 2015 | 0.9000 |
| ▸2014 |
0.60 EUR
|
| March 21, 2014 | 0.6000 |
| ▸2013 |
0.84 EUR
|
| Dec. 10, 2013 | 0.6000 |
| Aug. 6, 2013 | 0.2400 |
| March 22, 2013 | 0.0040 |
| ▸2012 |
0.00 EUR
|
| March 29, 2012 | 0.0040 |
| ▸2011 |
0.00 EUR
|
| April 1, 2011 | 0.0040 |
| ▸2010 |
0.00 EUR
|
| April 9, 2010 | 0.0020 |
| ▸2009 |
0.00 EUR
|
| April 16, 2009 | 0.0040 |
| ▸2008 |
0.01 EUR
|
| April 3, 2008 | 0.0080 |
| ▸2007 |
0.00 EUR
|
| April 4, 2007 | 0.0020 |
Community Discussion